{"disease":{"id":"castleman-s-disease","name":"Castleman's disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"tocilizumab","indication_name":"Castleman's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Roactemra","generic_name":"tocilizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Interleukin-6 receptor","drug_class":"Interleukin-6 Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05283993","title":"A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT00006518","title":"Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1029,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03300830","title":"Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease","phase":"","overall_status":"RECRUITING","enrollment_count":280,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04968288","title":"Natural History of KSHV-Associated Multicentric Castleman s Disease","phase":"","overall_status":"RECRUITING","enrollment_count":195,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01552434","title":"Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01024036","title":"A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT01400503","title":"A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT04743687","title":"Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03982771","title":"BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05345522","title":"A Study of Anti-IL-6R mAb Injection in Patients With iMCD","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Beijing VDJBio Co., LTD.","has_results":false},{"nct_id":"NCT04838860","title":"Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"RECORDATI GROUP","has_results":false},{"nct_id":"NCT05440305","title":"Unicentric Form of Castleman Disease - Surgery Therapy Benefit","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Charles University, Czech Republic","has_results":false},{"nct_id":"NCT07085039","title":"Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":14,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT01441063","title":"Tocilizumab for KSHV-Associated Multicentric Castleman Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03933904","title":"Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7,"lead_sponsor_name":"University of Pennsylvania","has_results":true}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}